Traditionally viewed as an immunosuppressive factor, recent evidence suggests it can have context-dependent anti-tumor functions, particularly when administered in long-acting forms that can activate tumor-resident CD8+ T cells and reverse T cell exhaustion [43,48,49,50]. Here, CD8A is linked to neoplasm.